Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

SpringerPlus

Table 2 Association between baseline factors and change in GGT following fibrate treatment

Model 1: linear regression analysis with change in GGT as the dependent variable and the following as independent variables in separate analyses
	n	Co-efficient	95% C.I.	p-value
Gender (male)	116	−21.04	−37..03- –5.06	0.010
Pre-TC	115	−3.28	−6.18- –0.38	0.027
Pre-TG	116	−1.08	−2.03- –0.14	0.025
Pre fibrate GGT	116	−0.47	−0.56- –0.38	<0.001
Pre fibrate ALT	114	−0.28	−0.51- –0.05	0.0180
Treatment duration	117	19.7	1.35-38.0	0.036
change in HDL-C	98	−33.79	−57.19- –10.38	0.005
Model 2: multiple regression analysis with change in GGT as the dependent variable and the following as independent variables in a single analysis.
	n	Co-efficient	95% C.I.	p-value
Gender (male)	96 (r² = 0.52)	−5.47	−18.77-7.83	0.42
Pre-TC		0.48	−3.81-4.77	0.83
Pre-TG		−1.43	−3.77-0.91	0.23
Pre fibrate GGT		−0.44	−0.56- –0.31	<0.001
Pre fibrate ALT		0.07	−0.12-0.26	0.48
Treatment duration		12.5	1.86-26.9	0.087
change in HDL-C		−24.61	−55.42-6.22	0.12

Age, pre-fibrate HDL-C, pre-fibrate ALP, pre-fibrate creatinine, change in TC, change in TG were not significantly associated with changes observed in GGT following fibrate treatment.